Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015:2015:250812.
doi: 10.1155/2015/250812. Epub 2015 Jun 2.

Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives

Hua Zhang  1 , Xufeng Dai  1 , Yan Qi  1 , Ying He  1 , Wei Du  2 , Ji-Jing Pang  3
Affiliations
Review

Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives

Hua Zhang et al. J Ophthalmol. 2015.

Abstract

Retinal degenerative diseases are one of the important refractory ophthalmic diseases, featured with apoptosis of photoreceptor cells. Histone acetylation and deacetylation can regulate chromosome assembly, gene transcription, and posttranslational modification, which are regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively. The histone deacetylase inhibitors (HDACis) have the ability to cause hyperacetylation of histone and nonhistone proteins, resulting in a variety of effects on cell proliferation, differentiation, anti-inflammation, and anti-apoptosis. Several HDACis have been approved for clinical trials to treat cancer. Studies have shown that HDACis have neuroprotective effects in nervous system damage. In this paper, we will summarize the neuroprotective effects of common HDACis in retinal degenerative diseases and make a prospect to the applications of HDACis in the treatment of retinal degenerative diseases in the future.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Possible mechanisms of HDACis in the prevention of retinal degenerative diseases. HDACis acetylate histone and nonhistone proteins, such as AcH3, AcH4, and HSP70, regulate transcription process. HDACis promote cell regeneration and proliferation, improve cell survival, enhance anti-inflammatory effects, attenuate cell apoptosis, and upregulate the expression of neurotrophic factors.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Huang C., Sloan E. A., Boerkoel C. F. Chromatin remodeling and human disease. Current Opinion in Genetics and Development. 2003;13(3):246–252. doi: 10.1016/S0959-437X(03)00054-6. - DOI - PubMed
    1. Simone C., Peserico A. Physical and functional HAT/HDAC interplay regulates protein acetylation balance. Journal of Biomedicine and Biotechnology. 2011;2011:10. doi: 10.1155/2011/371832.371832 - DOI - PMC - PubMed
    1. Giannini G., Cabri W., Fattorusso C., Rodriquez M. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Medicinal Chemistry. 2012;4(11):1439–1460. doi: 10.4155/fmc.12.80. - DOI - PubMed
    1. Chuang M.-J., Wu S.-T., Tang S.-H., et al. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation. PLoS ONE. 2013;8(9) doi: 10.1371/journal.pone.0073401.e73401 - DOI - PMC - PubMed
    1. Feng W., Zhang B., Cai D., Zou X. Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. Cancer Letters. 2014;347(2):183–190. doi: 10.1016/j.canlet.2014.02.012. - DOI - PubMed